6.13
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sy…
β-receptor blockers or β-adrenoceptor antagonists bind to β receptors and inhibit catecholamine-mediated sympathetic responses.
All β blockers are competitive antagonists but differ in characteristics such as adrenoceptor subtype affinity, lipophilicity, and α-blockade ability.
β blockers are categorized as either nonselective or selective.
The first β blocker was dichloroisoprenaline with partial agonist activity. Further research led to the development of propranolol, which was a pure antagonist but nonselective agent.
Next, propranolol analogs were further explored to obtain clinically effective drugs with β1-selectivity. For instance, practolol and atenolol are β1-selective.
Few selective β1 antagonists, like metoprolol, showed cardioselective actions.
Additionally, β blockers are also categorized generation-wise. The first generation includes older, nonselective molecules, while the second comprises cardioselective molecules.
The third generation includes newer drugs such as labetalol and carvedilol with additional α blocking or vasodilatory action. These drugs are therapeutically important in treating heart ailments and hemodynamic disorders.
View the full transcript and gain access to JoVE Core videos
Q1: How do β-blockers work to inhibit sympathetic responses?
β-blockers bind competitively to β receptors and inhibit catecholamine-mediated sympathetic responses. All β blockers function as competitive antagonists, but they differ in characteristics such as adrenoceptor subtype affinity, lipophilicity, and α-blockade ability. This mechanism makes them effective in modulating the sympathetic nervous system.
Q2: What distinguishes selective β1-blockers from nonselective β-blockers?
Selective β1-blockers like atenolol and metoprolol target primarily β1 receptors, providing cardioselective actions that benefit heart function. Nonselective β-blockers such as propranolol affect both β1 and β2 receptors. This selectivity allows clinicians to tailor therapy based on therapeutic goals and patient-specific conditions.
Q3: What was the first β-blocker developed, and how did it differ from propranolol?
Dichloroisoprenaline was the prototype β-blocker but exhibited partial agonist activity. Propranolol was subsequently developed as a pure antagonist, though it remained nonselective. This advancement eliminated unwanted agonist effects while establishing the foundation for developing more targeted β-blocking agents with improved selectivity.
Q4: How are β-blockers classified by generation, and what defines each generation?
First-generation β-blockers are older, nonselective molecules like propranolol. Second-generation drugs are cardioselective agents such as atenolol and metoprolol. Third-generation includes newer drugs like labetalol and carvedilol with additional α-blocking or vasodilatory actions, offering expanded therapeutic benefits for diverse patient populations.
Q5: What additional properties do third-generation β-blockers like carvedilol and labetalol provide?
Third-generation β-blockers such as carvedilol and labetalol possess dual α-blocking or vasodilatory properties in addition to β-blockade. These combined actions offer therapeutic advantages in managing hypertension and heart failure by simultaneously targeting both α- and β-adrenergic receptors, providing more comprehensive sympathetic modulation.
Q6: Why is lipophilicity an important characteristic distinguishing different β-blockers?
Lipophilicity affects a β-blocker's ability to cross the blood-brain barrier and penetrate tissues. β-blockers differ in lipophilicity, which influences their distribution, metabolism, and clinical effects. This characteristic, along with adrenoceptor subtype affinity and α-blockade ability, determines how each drug behaves pharmacologically and therapeutically.
Q7: What clinical conditions benefit from β-blocker therapy?
β-blockers are therapeutically important in treating heart ailments and hemodynamic disorders. Their ability to inhibit catecholamine-mediated sympathetic responses makes them valuable for managing conditions like hypertension, heart failure, and arrhythmias. The diversity of β-blocker types allows selection based on specific patient needs and disease characteristics.